Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2016 - 2024)

Historic Total Non-Current Liabilities for Intellia Therapeutics (NTLA) over the last 8 years, with Q4 2024 value amounting to $189.1 million.

  • Intellia Therapeutics' Total Non-Current Liabilities fell 2462.0% to $189.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $189.1 million, marking a year-over-year decrease of 2462.0%. This contributed to the annual value of $189.1 million for FY2024, which is 2462.0% down from last year.
  • Intellia Therapeutics' Total Non-Current Liabilities amounted to $189.1 million in Q4 2024, which was down 2462.0% from $250.8 million recorded in Q4 2023.
  • Intellia Therapeutics' Total Non-Current Liabilities' 5-year high stood at $260.5 million during Q4 2022, with a 5-year trough of $189.1 million in Q4 2024.
  • For the 4-year period, Intellia Therapeutics' Total Non-Current Liabilities averaged around $230.4 million, with its median value being $232.6 million (2022).
  • In the last 5 years, Intellia Therapeutics' Total Non-Current Liabilities soared by 247.19% in 2022 and then crashed by 2462.0% in 2024.
  • Intellia Therapeutics' Total Non-Current Liabilities (Quarter) stood at $254.2 million in 2021, then grew by 2.47% to $260.5 million in 2022, then dropped by 3.72% to $250.8 million in 2023, then decreased by 24.62% to $189.1 million in 2024.
  • Its Total Non-Current Liabilities stands at $189.1 million for Q4 2024, versus $250.8 million for Q4 2023 and $205.9 million for Q3 2023.